Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,929
Views
5
CrossRef citations to date
0
Altmetric
Letter to the Editor

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study

Luciano Ibbaa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyCorrespondence[email protected]
View further author information
,
Luigi Gargiuloa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
,
Angela Alfanoa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
,
Ruggero Cascio Ingurgioa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
,
Alessandra Narcisia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
,
Antonio Costanzoa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
&
Mario Valentia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
 show all
Article: 2199108 | Received 29 Mar 2023, Accepted 30 Mar 2023, Published online: 14 Apr 2023

References

  • Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):1–3.
  • Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.
  • Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790.
  • Valenti M, Gargiulo L, Ibba L, et al. Sub-erythrodermic psoriasis successfully treated with bimekizumab: a case report. Dermatol Ther. 2022;35(12):e15952.
  • Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31(10):1686–1692.
  • Au SC, Goldminz AM, Kim N, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat. 2013;24(3):179–187.
  • Paul C, Reich K, Gottlieb AB, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28(12):1670–1675.
  • Al Muqrin AM, Alghamdi AA, AlShaalan ZM. Rapid response of palmoplantar psoriasis to risankizumab: a case report. Clin Cosmet Investig Dermatol. 2022;15:2129–2132.
  • Gambardella A, Licata G, Tancredi V, et al. A case of refractory palmoplantar psoriasis treated with tildrakizumab. Ital J Dermatol Venerol. 2022;157(4):379–380.
  • Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Acad Dermatol Venereol. 2023;00:1–11. doi:10.1111/jdv.18913.
  • Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–2820.
  • Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.